Trial Profile
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Ischaemia; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALPHEUS
- 01 Jan 2024 Results assessing the impact of the P2Y12 inhibitor loading time on periprocedural myocardial necrosis, published in the Canadian Journal of Cardiology
- 28 Aug 2023 Results of post hoc analysis assessing the the frequency and outcomes of complex PCI in stable coronary patients and the efficacy of ticagrelor versus clopidogrel in these patients randomized in the ALPHEUS trial, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
- 28 Dec 2020 Results of meta-analysis comparing safety and efficacy of pP2Y12-I versus Clopidogrel in patients with CAD undergoing elective PCI published in the American Journal of Cardiology